Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Platelet stimulating agents — off the launching pad

Nature Medicine volume 3, pages 154–155 (1997)Cite this article

Promising clinical trial data suggest that thrombopoietic growth factors may soon enter clinical practice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Metcalf, D. Thrombopoietin – at last. Nature 369, 519–520 (1994).

    Article  CAS  Google Scholar 

  2. Gurney, A.L., Carver-Moore, K., de Sauvage, F.J. & Moore, M.W. Thrombocytopenia in c-mpl-deficient mice. Science 265, 1445–1447 (1994).

    Article  CAS  Google Scholar 

  3. de Sauvage, F. et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J. Exp. Med. 183, 651–656 (1996).

    Article  CAS  Google Scholar 

  4. Kaushansky, K. et al. Thrombopoietin, the mpl lig-and, is essential for full megakaryocyte develop-ment. Proc. Natl. Acad. Sci. USA 92, 3234–3238 (1995).

    Article  CAS  Google Scholar 

  5. Shivdasani, R.A. et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MCDF in megakary-ocyte development. Cell 81, 695–704 (1995).

    Article  CAS  Google Scholar 

  6. Tepler, I. et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87, 3607–3614 (1996).

    CAS  PubMed  Google Scholar 

  7. Basser, R.L. et al. Thrombopoietic effects of pegy-lated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348, 1279–1281 (1996).

    Article  CAS  Google Scholar 

  8. Archimbaud, E. et al. A randomized, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia (AML): Early results (Abstr.). Blood 88, (Suppl. 1), 447a (1996).

    Google Scholar 

  9. Vadhan-Raj, S. et al. Phase l-ll investigation of re-combinant human thrombopoietin (rhTPO) in pa-tients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifos-famide (I) (Abstr.). Blood 88, (Suppl. 1), 448a (1996).

    Google Scholar 

  10. O'Malley, C.J. et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vitro activation. Blood 88, 3288–3298 (1996).

    CAS  PubMed  Google Scholar 

  11. Groopman, J.E., Mitsuyasu, R.T., DeLeo, M.J., Oette, D.H. & Golde, D.W. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. New Engl. J. Med. 317, 593–598 (1987).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, USA

    Stephen D. Nimer

Authors
  1. Stephen D. Nimer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nimer, S. Platelet stimulating agents — off the launching pad. Nat Med 3, 154–155 (1997). https://doi.org/10.1038/nm0297-154

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0297-154

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing